Scope of report
- The report provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy.
- The report assesses Duchenne Muscular Dystrophy pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Duchenne Muscular Dystrophy pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Duchenne Muscular Dystrophy ranging from discovery to pre-registration and undisclosed stages.
FibroGen, Collgard Biopharmaceuticals, ProSkelia, GTx; Merck & Co, ViroMed Co Ltd, PTC Therapeutics, VASTox, Asklepios BioPharmaceutical, Prosensa, AVI BioPharma, Ercole Biotech, Acceleron Pharma, Amsterdam Molecular Therapeutics, Beike Biotechnology, Catabasis Pharmaceuticals, Tarix Pharmaceuticals, Karyopharm Therapeutics, Phrixus Pharmaceuticals, ReveraGen BioPharma, Retrophin, Pfizer
Pirfenidone, Pamrevlumab, AEOL 10150, Sonolisib, Nintedanib, Tipelukast, Lebrikizumab, STX 100, Carlumab, Dectrekumab, Tanzisertib, PBI 4050, PRM 151, Omipalisib
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800